Arkolith/Insider Trading/HILS/Form 4

Mazur Leonard L

DirectorHillstream BioPharma Inc. (HILS) · full profile →Form 4 · filed Jan 18, 2022
Net Buying
Open-Market Buys
$100K
Open-Market Sells
$0
Net Open-Market Flow
$100K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 14, 2022Conversion(C)99K$3.20$316K99K
Jan 14, 2022Buy(P)25K$4.00$100K124K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 14, 2022Conversion(C)0—$00

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-22-001473) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML